Navigation Links
Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma therapy market will experience robust annual growth of more than 11 percent from 2012 to 2022 in the world's major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Immunotherapies will continue to dominate the malignant melanoma market through 2022. Sales for this drug class will increase dramatically during this period owing primarily to the anticipated launches of the immune checkpoint inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, for treatment of unresectable and metastatic melanoma and the anticipated adjuvant line-extension of Bristol-Myers Squibb's Yervoy. In 2022, sales of immunotherapies for melanoma will total more than $2.1 billion with sales of immune checkpoint inhibitors accounting for the vast majority of these sales.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor report entitled Malignant Melanoma finds that the BRAF/MEK inhibitor drug class will continue to play an important role in treatment of BRAF V600-mutation-positive unresectable and metastatic melanoma and that BRAF/MEK inhibitor combination therapy will become the preferred treatment approach over BRAF and MEK inhibitor monotherapy owing to its anticipated improved efficacy and safety and tolerability compared with monotherapy treatment. By 2022, three BRAF/MEK inhibitor combination therapies will launch, the first of which will be GlaxoSmithKline's Tafinlar/Mekinist, in 2014, in the United States and Europe. All BRAF/MEK inhibitor combination therapies will compete for market share in the unresectable/metastatic BRAF V600-mutation-positive patient population, with sales of this drug class accounting for one-fifth of the total market in 2022.

The report also finds that, despite the anticipated launch of several novel premium-priced therapies during the 2012-2022 forecast period, Yervoy will remain the sales leader through 2022 due to the agent's high price, its anticipated line-extension into the adjuvant setting and its anticipated first-line use in combination with nivolumab for unresectable/metastatic disease.

"When considering the melanoma clinical development pipeline, interviewed thought leaders are most excited about the immune checkpoint inhibitors," said Decision Resources Senior Business Insights Analyst, Karen Pomeranz, Ph.D. "We forecast that nivolumab and MK-3475 will launch for treatment of melanoma in all markets under study, attaining their highest sales in the first-line unresectable/metastatic setting. In 2022, nivolumab and MK-3475 will earn overall major market sales of nearly $1.1 billion."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
2. CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
3. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
4. Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%;
5. Widespread Acceptance and Use of Accurays Technologies Continue to Grow
6. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
7. STAAR Surgical Reports Continued Momentum During Third Quarter
8. Grant from Smith & Nephew Helps Continue Educational Activities for Podiatric Surgeons
9. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
10. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
11. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):